Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity raises target price on Taseko Mines

(Sharecast News) - Analysts at Canaccord Genuity lowered their target price on copper producer Taseko Mines from 305.0p to 290.0p on Tuesday as it updated its model on the stock following the group's Q125 numbers. Taseko's Q125 earnings revealed that production was in line with expectations, but the group also offered up "a less optimistic outlook" for its Gibraltar operations in 2025. Production of 20.0m pounds of copper was in line, while copper sales of 21.8m lbs, C1 costs of USD $2.26/lb and total site costs of CAD $107.0m beat estimates. However, adjusted underlying earnings of CAD $34.0m fell short as the use of stockpiles led to a "large" inventory movement for the quarter.

The Canadian bank also noted that Taseko's management elaborated on the reason for the downgrade in guidance at Gibraltar to 110-120m lbs from 120-130m lbs, explaining that the "overburden" surrounding the upper benches of its Connector pit was "more challenging than expected", leading to lower mining rates.

"We have updated our estimates for the 1Q25 release, and the lower production expectation for Gibraltar. We now assume 111m lbs (the lower end of the guidance range) for FY25, and expect a spike in C1 costs in 2Q25 to US$2.69/lb (as a higher proportion of mining costs are expensed rather than capitalised). Our FY25 EBITDA estimate is now -13% lower, and our NAV/share has fallen to 386p/C$7.07 (from 416p/C$7.55). We lower our target price to 290p/C$5.30 (from 305p/C$5.55). We use a combination of 12-month forward EBITDA growth and 1x P/NPV (rounded to the nearest 5p) in setting our target price," said Canaccord Genuity, which reiterated its 'buy' rating on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.